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Abstract
Background: Atrial fibrillation (AF) is a common cardiac arrhythmia that is associated with significant health risks.
One strategy to mitigate the risks associated with long-term AF is to convert AF to sinus rhythm (SR). This study
assessed the efficacy and safety of vernakalant hydrochloride for the pharmacological conversion of AF to SR.
Methods: Patients with recent-onset (duration >3 h– ≤ 7 days) symptomatic AF and no evidence or history of
congestive heart failure were randomized in a 2:1 ratio to receive vernakalant or placebo. Patients received an
infusion of vernakalant (3 mg/kg) or placebo over 10 min, followed by a second infusion of vernakalant (2 mg/kg) or
placebo 15 min later if AF had not been terminated. The primary efficacy endpoint was conversion of AF to SR for at
least 1 min within 90 min of the start of drug infusion. The primary safety endpoint was a composite of: occurrence of
clinically significant hypotension, clinically significant ventricular arrhythmia (including torsades de pointes, ventricular
tachycardia or ventricular fibrillation) or death within 2 h of starting the drug infusion.
Results: A total of 217 patients were randomized to receive vernakalant (n = 145) or placebo (n = 72). Of the 129
individuals who received vernakalant, 59 (45.7 %) converted to SR compared with one of the 68 patients (1.5 %)
who received placebo (p < 0.0001). Conversion to SR was significantly faster with vernakalant than with placebo
(p < 0.0001), and a greater proportion of patients who received vernakalant than those who received placebo
reported no AF-related symptoms at 90 min (p = 0.0264). The primary composite safety endpoint was observed in
one patient receiving vernakalant and in no patients receiving placebo. In the vernakalant arm, dysgeusia, paraesthesia
and sneezing were the most common treatment-emergent adverse events, and three serious adverse events occurred
that were considered to be related to study drug.
Conclusions: Vernakalant resulted in rapid cardioversion of recent-onset AF in almost half of the study population and
was generally well tolerated. The safety outcomes affirmed the need for careful selection and management of
haemodynamically stable candidates for cardioversion.
Trial registration: NCT00989001.
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Background
Atrial fibrillation (AF) is the most common arrhythmia
encountered in clinical practice; projections suggest 3.3
million adults in the USA will have AF by 2020 [1]. Al-
though not directly life-threatening, AF may be a marker
of mortality and increases cardiovascular morbidity; AF
is associated with an increased long-term risk of stroke
and heart failure [2]. A desired strategy to mitigate some
of the risks associated with AF remains the conversion of
AF to normal sinus rhythm (SR). This conversion can be
achieved via electrical cardioversion (ECV) or pharmaco-
logical cardioversion, both of which are widely used [3].
While ECV is generally more efficacious than pharmaco-
logical cardioversion, it can be associated with dermal in-
jury, arrhythmias, thromboembolic complications and
early recurrence of AF, and patients must be anaesthetized
during the procedure [4–8]. At the time of the present
clinical trial, the available pharmacological agents had
been shown to have limited efficacy in converting AF to
SR and to have the potential for causing serious arrhyth-
mias or hypotension [5, 9, 10].
Vernakalant hydrochloride is a novel, and relatively
atrial-selective, antiarrhythmic agent that rapidly and
durably converts recent-onset AF to SR [11, 12]; it has
been shown to be more effective than amiodarone for
rapid conversion of AF of 3–48 h’ duration [13]. Previous
randomized, double-blind, placebo-controlled trials have
demonstrated that, compared with placebo, intravenous
vernakalant effectively converts AF to SR in patients with
recent-onset AF (duration >3 h– ≤ 7 days; p < 0.001 in
both Arrhythmia Conversion Trial [ACT] I and ACT III)
[12, 14]. These studies also identified that patients with
low baseline systolic blood pressure (SBP) and congestive
heart failure (CHF) receiving vernakalant may be at an
increased risk of hypotension [15]. This randomized,
double-blind, placebo-controlled phase 3b clinical trial
investigated the safety and efficacy of vernakalant hydro-
chloride for the conversion of symptomatic recent-onset
AF to SR in patients with no history or evidence of CHF.
Methods
Study design
This multicentre study involved 113 sites in Canada,
Chile, Israel, Mexico, Peru, South Africa and the USA; 58
of the 113 sites enrolled at least one patient. The study
was conducted under the terms of a Special Protocol As-
sessment (SPA) procedure (Guidance for Industry Special
Protocol Assessment, May 2002); comments received
from the US Food and Drug Administration (FDA) and
subsequent revisions to the study protocol were addressed
and clearly documented as part of the formal SPA
process. The protocol and amendments to the protocol
were reviewed and approved by an Independent Ethics
Committee or Institutional Review Board at each study
site. The study was overseen by the sponsors, an inde-
pendent Data Safety Monitoring Board (DSMB) and
Clinical Events Committee (CEC), and was conducted
in accordance with the Declaration of Helsinki, Good
Clinical Practice and International Council for Har-
monisation guidelines, as well as applicable laws and
regulations. All included patients provided written in-
formed consent.
Patient screening and selection
Patients who were candidates for participation in the
study were assessed before enrolment, within 12 h be-
fore dosing. Screening included assessment of inclusion
and exclusion criteria. Included patients were adults
aged 18 − 85 years with recent-onset (duration >3 h– ≤
7 days) symptomatic AF for whom best management
was determined by the investigator to be acute cardio-
version to SR. Patients were also required to be ad-
equately hydrated (as determined by the investigator). If
AF had continued for more than 48 h, patients were to
be managed in accordance with the standard of care
for anticoagulation, as recommended by the American
College of Cardiology/American Heart Association/
European Society of Cardiology guidelines [16]. Patients
were excluded if they had evidence or a history of heart
failure or evidence of left ventricular dysfunction, heart
rate less than 50 beats per minute (bpm) or symptomatic
bradycardia. Additional inclusion and exclusion criteria
were the same as those detailed in Roy et al. [12]. For
example, patients were excluded if they met any of the
following criteria: had a QRS interval of more than
0.14 s without a pacemaker; an uncorrected QT interval
of more than 0.44 s; acute coronary syndrome or myo-
cardial infarction; or cardiac surgery performed in the
30 days before planned enrolment [12].
Treatment plan
Patients were randomized in a 2:1 ratio to receive verna-
kalant or placebo. Participants received either a 10-min
intravenous infusion of vernakalant (3 mg/kg) or an
equivalent volume of placebo (normal saline). They were
then observed for 15 min; if patients were in AF or
atrial flutter at the end of the observation period, a
second 10-min infusion of vernakalant (2 mg/kg) or
equivalent volume of placebo was administered, unless
any dose-stopping criteria had been met. Dose-stopping
criteria were similar to those listed in Roy et al. [12]
and comprised: an uncorrected QT interval of more
than 0.55 s or QT interval prolonged by more than
25 % compared with the baseline value; a heart rate of
40–50 bpm alongside symptoms of bradycardia, or a
heart rate less than 40 bpm; SBP less than 85 mmHg;
new bundle-branch block; QRS interval prolonged by
more than 50 % compared with baseline; asymptomatic
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ventricular tachycardia lasting 30 s or longer; symptom-
atic ventricular tachycardia; ventricular fibrillation;
torsades de pointes of any duration; sinus pause of 5 s
or longer; complete heart block; or intolerable side
effects as assessed by the investigator.
ECV was permitted 2 h after the start of the first infu-
sion of study drug if the patient was still in AF or atrial
flutter. Patients were observed in hospital for a mini-
mum of 4 h after the start of infusion of the study drug.
Vital signs were recorded at screening, baseline, every
5 min from the start of infusion until 1 h post-infusion,
then every 30 min until 4 h post-infusion, and at 24 h
and 1 week post-infusion. Continuous Holter monitoring
was performed from 30 min before the start of the infu-
sion until 24 ± 4 h later. Several 12-lead electrocardio-
grams (ECGs) were recorded, including at screening and
baseline, at the start and end of the infusion(s), at AF
conversion, every 30 min from 1 to 4 h post-infusion,
and at 24 h and 1 week post-infusion. In patients in
whom ECV was attempted, additional monitoring of
vital signs and ECGs was carried out between the time
that conscious sedation was initiated and 2 h after the
last electrical shock.
Study outcomes
The primary efficacy endpoint was successful conversion
to SR for at least 1 min within 90 min of the start of the
first infusion. The main outcome variable was the propor-
tion of patients achieving this endpoint based on inde-
pendent CEC assessment of ECG/Holter data. Secondary
efficacy variables were the time between first exposure to
study drug and conversion of AF to SR, and the propor-
tion of patients reporting no AF symptoms at 90 min after
first drug exposure. Exploratory efficacy variables included
the proportion of patients who converted to SR within
90 min and maintained SR for 24 h following first
exposure to the study drug (sustained conversion rate),
and the impact of symptoms of AF on quality of life at
90 min after first drug exposure.
The primary safety outcome was the proportion of
patients who met any of the following three criteria, as
assessed by the independent CEC: clinically significant
hypotension; clinically significant ventricular arrhythmia;
or death within 2 h of the start of exposure to study drug.
Clinically significant hypotension was defined as any of
the following: SBP of less than 90 mmHg with treatment
with pressors, SBP of less than 90 mmHg with albumin,
dextran or hydroxyethyl starch treatment, or SBP of less
than 90 mmHg and seizures. Ventricular arrhythmia was
defined as any of the following: sustained ventricular
tachycardia (lasting ≥30 s on ECG, telemetry or Holter
monitoring) with a heart rate of at least 120 bpm, torsades
de pointes with a duration of 10 s or more on Holter or
12-lead ECG, or ventricular fibrillation of any duration.
Statistical analysis
All randomized patients who received any amount of
study drug were included in the efficacy and safety
analyses. All analyses were performed using Statistical
Analysis Systems 9.2 (SAS® Institute, Cary, NC, USA).
Baseline demographics and patient characteristics were
summarized by treatment group. For continuous data,
summaries included the number of observations, and mean,
standard deviation (SD) and median values. For categorical
data, frequency counts and percentages were presented.
A sample size of 450 patients was planned, based on
the primary safety endpoint. The primary safety objective
of the study was to demonstrate a less than 1 % risk of
clinically significant events with vernakalant, based on
requirements set by the US FDA. With 300 patients
treated with vernakalant and no events, the risk of clinic-
ally significant events would be less than 1 %, as defined
by the one-sided upper 95 % confidence interval (C.I) for
the vernakalant arm. To prevent any bias, a placebo group
of 150 participants was planned. This total sample size of
450 patients would have provided more than 98 % power
to detect a treatment difference of 35 % in the primary
efficacy endpoint, assuming a cardioversion rate of less than
10 % in the placebo group. Estimation of the C.I for the pri-
mary safety endpoint was based on the exact approach.
The primary efficacy endpoint was analysed using the
Cochran–Mantel–Haenszel test stratified by geographic
region. If the primary efficacy endpoint demonstrated
a statistically significant positive finding, each of the
secondary efficacy endpoints was analysed. For the time to
conversion of AF to SR, the Kaplan–Meier method was
used to obtain the distribution of the time to conversion
associated with each treatment group. The two treatment
groups were then compared using a two-sided log-rank
test. For the proportion of patients reporting no symp-
toms at 90 min, data were analysed using a two-sided χ2
test. Analyses of the exploratory efficacy variables were
conducted using two-sided χ2 tests.
Results
Between 28 October 2009 and 21 October 2010, 217
patients were enrolled in the study and randomized to
receive either vernakalant (n = 145) or placebo (n = 72).
The majority of randomized patients (197 of 217) received
at least one infusion of study drug and were included in
the efficacy and safety analyses. Patient enrolment was
suspended and the study was placed on clinical hold on
21 October 2010, after a single patient in the vernakalant
arm experienced the primary safety outcome. Following a
meeting with the US FDA in December 2011, it was
determined by the sponsors that this study would not
meet regulatory expectations. Therefore, the study was
terminated early.
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Baseline demographics and characteristics
Demographics, medical history and characteristics of AF
were similar in the two treatment groups (Table 1). Over
half of the patients were from Israel (37.1 %) or the USA
(24.4 %), and the majority were white (95.4 %) and male
(61.4 %). Patients had a mean (± SD) age of 62.7 (±13.2)
years, and a mean weight of 87.6 (±17.7) kg. Cytochrome
P450 2D6 (CYP2D6) genotype status was known in
51.8 % of patients, most of whom were classified as ex-
tensive (57.8 %) or intermediate (31.4 %) metabolizers.
AF and medical history were similar in patients in the
two treatment groups. Most patients (60.9 %) had expe-
rienced at least one previous AF episode, and 16.8 % had
experienced more than three previous episodes. The me-
dian duration of patients’ current AF episode was 25 h.
Efficacy
Vernakalant met the primary and secondary efficacy
endpoints; a significantly greater proportion of patients
Table 1 Baseline patient demographics and characteristics





Male 45 (66.2) 76 (58.9)
Female 23 (33.8) 53 (41.1)
Race, n (%)
White 65 (95.6) 123 (95.3)
Black or African–American 0 5 (3.9)
Asian 2 (2.9) 0
American Indian or Alaskan Native 0 1 (0.8)
Other 1 (1.5) 0
Country, n (%)
Israel 24 (35.3) 49 (38.0)
USA 17 (25.0) 31 (24.0)
South Africa 15 (22.1) 21 (16.3)
Canada 9 (13.2) 20 (15.5)
Chile 2 (2.9) 3 (2.3)
Mexico 1 (1.5) 4 (3.1)
Peru 0 1 (0.8)
Age, years, mean (SD) 60.8 (14.1) 63.7 (12.7)
Weight, kg, mean (SD) 89.8 (17.6) 86.5 (17.7)
Classification based on CYP2D6 genotype, n (%)
Extensive metabolizer 17 (25.0) 42 (32.6)
Intermediate metabolizer 13 (19.1) 19 (14.7)
Poor metabolizer 0 4 (3.1)
Ultra-rapid metabolizer 0 2 (1.6)
Indeterminate 1 (1.5) 4 (3.1)
Missing 37 (54.4) 58 (45.0)
Number of previous AF episodes, n (%)
0 24 (35.3) 53 (41.1)
1 14 (20.6) 32 (24.8)
2 15 (22.1) 15 (11.6)
3 2 (2.9) 9 (7.0)
>3 13 (19.1) 20 (15.5)
Duration of current AF episode, hours,
mean (SD)
41.0 (36.3) 37.3 (36.6)
Duration of current AF episode, n (%)
1 day 28 (41.2) 62 (48.1)
2 days 16 (23.5) 25 (19.4)
3 days 8 (11.8) 13 (10.1)
4 days 5 (7.4) 8 (6.2)
5 days 1 (1.5) 7 (5.4)
6 days 6 (8.8) 3 (2.3)
7 days 0 2 (1.6)
Missing data 4 (5.9) 9 (7.0)
Table 1 Baseline patient demographics and characteristics
(Continued)
Medical history, n (%)
Hypertension 39 (57.4) 89 (69.0)
Hyperlipidaemia 39 (57.4) 62 (48.1)
Valvular heart disease 13 (9.1) 27 (20.9)
Diabetes mellitus 16 (23.5) 18 (14.0)
Ischaemic heart disease 12 (17.6) 18 (14.0)
Percutaneous transluminal coronary
angioplasty
9 (13.2) 18 (14.0)
Syncope, fainting or postural hypotension 10 (14.7) 9 (7.0)
Myocardial infarction 7 (10.3) 11 (8.5)
Angina pectoris 3 (4.4) 10 (7.8)
Atrial flutter 3 (4.4) 8 (6.2)
Coronary artery bypass graft 3 (4.4) 5 (3.9)
Pacemaker 3 (4.4) 3 (3.2)
Ventricular tachycardia 2 (2.9) 1 (0.8)
Symptoms of AF, n (%)
Palpitations n = 66 n = 128
42 (63.6) 88 (68.8)
Fatigue n = 65 n = 128
33 (50.8) 61 (47.7)
Chest pain n = 66 n = 128
5 (7.6) 17 (13.3)
Dyspnoea n = 66 n = 128
10 (15.2) 26 (20.3)
Dizziness n = 66 n = 128
13 (19.7) 20 (15.6)
AF atrial fibrillation, SD standard deviation
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in the vernakalant group than in the placebo group con-
verted from AF to SR in the 90 min following first drug
exposure (45.7 % [n = 59 of 129] vs 1.5 % [n = 1 of 68],
respectively; p < 0.0001; Fig. 1). Conversion to SR was
significantly faster in the vernakalant group than in the
placebo group (p < 0.0001; Fig. 2); 25 % of patients re-
ceiving vernakalant had converted to SR by 11 min, and
the patient receiving placebo who met the primary effi-
cacy endpoint converted to SR after 84 min.
The proportion of patients reporting no AF symptoms
at 90 min was significantly greater in the vernakalant group
than in the placebo group (47.3 % vs 30.9 %, respectively;
p = 0.0264). In both treatment groups, the proportion
reporting AF symptoms was reduced at 90 min relative to
baseline. The degree to which symptoms of AF impacted
on quality of life had improved in patients who received
vernakalant compared with those who received placebo
(p = 0.0227) by 90 min. After 24 h, 56 of the 59 patients
(94.9 %) who received vernakalant and who had met
the primary efficacy endpoint were still in SR, as was
the patient who had converted to SR after receiving
placebo.
Safety
The primary composite safety endpoint was observed in
one patient receiving vernakalant who experienced
hypotension and ventricular arrhythmia within 2 h of
treatment initiation, and in no patients in the placebo
group. The primary safety endpoint was also observed
within 2 h of ECV in a patient who had previously
received vernakalant. The patient developed hypotension
16 h after the last vernakalant infusion: this was not
considered by the investigator to be related to
study drug.
The incidence of treatment-emergent adverse events
(AEs) was higher in the vernakalant group than in the
placebo group. Treatment-emergent AEs that occurred
within 24 h in more than 3 % of patients are listed in
Table 2. The majority of treatment-emergent AEs occur-
ring within 24 h of the start of infusion and considered
to be related to study drug were observed in the verna-
kalant group, with dysgeusia (14.7 %), sneezing (7.8 %)
and paraesthesia (6.2 %) being the most common.
The incidence of serious AEs (SAEs) occurring within
24 h of the start of study drug infusion was similar in
the two treatment groups (Table 3); SAEs occurred in 4
of 68 patients (5.9 %) who received placebo and 10 of
129 patients (7.8 %) who received vernakalant. SAEs that
occurred in more than one patient in the 24 h following
initiation of infusion included atrial fibrillation (two
patients in the placebo group and six patients in the
vernakalant group) and atrial flutter (two patients in the
vernakalant group). The proportion of patients with SAEs
that occurred between 24 h and 30 days after study drug
infusion was similar in both treatment groups: 14 of 68
patients (20.6 %) who received placebo and 22 of 129 pa-
tients (17.1 %) who received vernakalant. SAEs that
occurred in more than one patient in a treatment group
were atrial fibrillation (9 placebo, 16 vernakalant), atrial
flutter (0 placebo, 2 vernakalant) and non-cardiac chest
pain (2 placebo, 1 vernakalant). Three patients had SAEs
considered to be related to vernakalant; all occurred
within 2 h of dosing and led to discontinuation of
treatment (nausea, headache, confusional state and cold
sweat in one patient, sinus arrest in another patient and





























Fig. 1 Proportion of patients who converted to sinus rhythm.
Proportion of patients who converted to sinus rhythm within
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Fig. 2 Time to cardioversion. Kaplan–Meier plot of the time to
conversion from atrial fibrillation to sinus rhythm within 90 min of
the start of the first infusion of placebo or vernakalant
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discontinuations due to AEs was low and similar in the
two groups.
There were two deaths in the study: one in the vernaka-
lant group and one in the placebo group. The patient in
the vernakalant group who died was a 77-year-old man.
He was genotyped as a CYP2D6 extensive metabolizer
and had plasma levels of vernakalant within the expected
range. He had a medical history of hypertension and
chronic alcohol abuse. The patient was receiving con-
comitant medication, including enalapril and acetylsali-
cylic acid, and had had dyspnoea for approximately
1 week, persistent palpitations for 48–72 h and AF for
approximately 48 h before he presented to the hospital.
Assessment of AF symptoms during screening and at
baseline revealed the presence of palpitations and fatigue,
but no chest pain, dyspnoea or dizziness. The patient’s
blood pressure was 139/76 mmHg and oxygen saturation
while breathing room air was 96 %. A two-dimensional
echocardiogram performed before randomization while
the individual was in AF with a ventricular rate of
156 bpm revealed diffuse hypokinesis with an ejection
fraction of 44 %, and moderate left ventricular hyper-
trophy. He experienced cardiogenic shock with symp-
toms of sweating and nausea, together with decreased
blood pressure and heart rate, beginning 10 min after
the start of vernakalant infusion. Approximately 4 h
after the onset of cardiogenic shock, the patient was
electrically cardioverted to SR. From day 2 to day 10,
the patient had an SAE of rhabdomyolysis, two SAEs of
electromechanical dissociation, and AEs of gastritis and
encephalopathy. Additional SAEs reported and resulted
in a fatal outcome; these included: coagulopathy, aspir-
ation pneumonia, hepatic failure, acute renal failure
and sepsis (all beginning on day 2); anaemia (starting
on day 4); gastrointestinal haemorrhage (starting on
day 12); ischaemic colitis (starting on day 17); and
hypovolemic shock (starting on day 29). All of these
subsequent AEs and SAEs were assessed by the investi-
gator as not being related to study drug. The patient
died on day 29.
The patient in the placebo group who died was an 84-
year-old woman with a history of valvular heart disease,
hypertension, hyperlipidaemia, coronary artery bypass graft
surgery, myocardial infarction, a brain arteriovenous fistula
and a cerebrovascular accident. She was receiving concomi-
tant medication, including clopidogrel, hydrochlorothiazide
and olmesartan. The patient received two full infusions of
placebo, did not convert to SR and did not undergo ECV.
Oral sotalol was administered approximately 3 h after the
last infusion of placebo, and the patient spontaneously con-
verted to SR 2 h later. The patient had an SAE of cerebro-
vascular accident 9 days later and, on the same day, she
Table 2 Frequent treatment-emergent adverse events
Adverse event, n (%) Placebo (n = 68) Vernakalant (n = 129)
Dysgeusia 1 (1.5) 19 (14.7)
Sneezing 0 11 (8.5)
Paraesthesia 1 (1.5) 8 (6.2)
Headache 2 (2.9) 7 (5.4)
Hypertension 3 (4.4) 6 (4.7)
Hypotension 3 (4.4) 5 (3.9)
Nausea 1 (1.5) 5 (3.9)
Increased blood pressure 0 4 (3.1)
Ventricular tachycardia 0 4 (3.1)
Bradycardia 0 4 (3.1)
Pain 3 (4.4) 0
Treatment-emergent adverse events that occurred in more than 3 % of patients
within 24 h of placebo or vernakalant administration
Table 3 Serious adverse events
Serious adverse event, n (%) Placebo (n = 68) Vernakalant (n = 129)
Any SAE 4 (5.9) 10 (7.8)
Blood and lymphatic system disorders
Coagulopathy 0 1 (0.8)
Iron-deficiency anaemia 1 (1.5) 0
Cardiac disorders
Atrial fibrillation 2 (2.9) 6 (4.7)
Atrial flutter 0 2 (1.6)
Cardiogenic shock 0 1 (0.8)
Sinus arrest 0 1 (0.8)
Gastrointestinal disorders
Nausea 0 1 (0.8)
General disorders and administration site conditions
Non-cardiac chest pain 1 (1.5) 0
Hepatic failure 0 1 (0.8)
Infections and infestations
Sepsis 0 1 (0.8)
Musculoskeletal and connective tissue disorders
Rhabdomyolysis 0 1 (0.8)
Nervous system disorders
Headache 0 1 (0.8)
Psychiatric disorders
Confusional state 0 1 (0.8)
Renal and urinary disorders
Acute renal failure 0 1 (0.8)
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration 0 1 (0.8)
Skin and subcutaneous tissue disorders
Cold sweat 0 1 (0.8)
Serious adverse events that occurred within 24 h after patients received
vernakalant or placebo
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experienced respiratory failure, cardiovascular arrest and
acute renal failure; these SAEs were all assessed by the in-
vestigator as not being related to study drug. The patient
died due to the cerebrovascular accident, approximately 7 h
after this event.
Discussion
Intravenous vernakalant is approved in European and
other countries as a relatively atrial-selective antiarrhyth-
mic drug for the conversion of recent-onset AF to SR.
This phase 3b study aimed to evaluate the safety and ef-
ficacy of vernakalant compared with placebo in patients
with recent-onset (duration >3 h– ≤ 7 days) symptomatic
AF and no evidence or history of CHF. Due to the small
number of CYP2D6 poor metabolizers enrolled, it was
not possible to determine from the data whether
CYP2D6 genotype had any influence on the occurrence
of adverse events in this study.
The study met all of the primary and secondary efficacy
objectives; treatment with vernakalant resulted in a signifi-
cantly greater proportion of patients converting from AF to
SR within the first 90 min (45.7 % vs 1.5 %, respectively)
and at a faster conversion rate than with placebo. Most par-
ticipants (94.9 %) who converted to SR reported sustained
conversion at 24 h. Furthermore, a greater proportion of
patients in the vernakalant group than in the placebo group
reported no AF symptoms at 90 min. The speed and
durability of conversion in this study are consistent with
the results of all previous studies of intravenous vernaka-
lant for patients with recent-onset AF [12–14, 17–20].
In terms of safety, vernakalant was well-tolerated in
most patients. The primary composite safety endpoint
was observed in one patient receiving vernakalant and in
no patients in the placebo group. One patient also met
the criteria for hypotension within 2 h of ECV, 16 h after
receiving vernakalant, but this was not considered by the
study investigator to be related to study drug. The inci-
dence of treatment-emergent AEs was higher in the ver-
nakalant group than in the placebo group; the most
commonly reported treatment-emergent AEs (dysgeusia,
sneezing and paraesthesia) were the same as those re-
ported in previous trials [12, 14]. Drug-related SAEs oc-
curred in three patients in the vernakalant group; one of
these events, cardiogenic shock, was unexpected and led
to the suspension of study enrolment. In addition, the
United States Investigational New Drug Application was
placed on clinical hold by the US FDA. This patient sub-
sequently experienced a series of AEs and SAEs and died
from lower gastrointestinal bleeding and multi-organ
failure. Although the independent DSMB recommended
that the trial continue after reviewing these data, it was
terminated by the sponsors [21].
It may be worth reviewing the safety events in this
study in the context of cardioversion of AF in clinical
practice. While ECV is generally regarded as an effective
treatment with a good safety profile, recently published
large registry studies have allowed a more systematic
evaluation. Pisters et al. reported on 1801 patients under-
going cardioversion at enrolment into the multicentre
prospective Euro Heart Survey on AF [6]. Major compli-
cations in the peri-procedural period in the ECV group
included: non-sudden cardiac death (2 patients [0.3 %]),
sick sinus syndrome (5 patients [0.7 %]), ventricular tachy-
cardia (6 patients [0.8 %]), torsades de pointes (1 patient
[0.1 %]), ventricular fibrillation (3 patients [0.4 %]), asystole
(2 patients [0.3 %]), cardiac syncope (1 patient [0.1 %]),
new heart failure (7 patients [1.1 %]), transient ischaemic
attack (2 patients [0.3 %]), stroke (2 patients [0.3 %]) and
major bleeding patients (9 [1.3 %]). Grönberg et al. re-
ported on the immediate arrhythmic complications fol-
lowing 6906 ECVs performed in 2868 patients with AF
of less than 48 h’ duration in the Finnish CardioVersion
(FinCV) study conducted between 2003 and 2010 [22].
In total, 63 ECVs (0.9 %) resulted in bradyarrhythmia,
defined as asystole lasting longer than 5 s and/or brady-
cardia of less than 40 bpm. A further analysis of the
retrospective data from the FinCV study was performed
by Nuotio et al. [23]. In addition to reporting that in-
creasing age, female sex, diabetes mellitus and heart
failure were risk factors for thromboembolism, these
authors reported that time to cardioversion was poten-
tially an important new determinant of stroke risk in
patients with AF of less than 48 h’ duration who were
not being treated with anticoagulants (N = 5116). It was
reported that a delay in time to cardioversion of 12 h
or longer from symptom onset was associated with a
1.1 % risk of thromboembolic complications; when the
duration of AF was less than 12 h, the risk of thrombo-
embolism was almost fourfold lower (0.3 %). Further
studies are required to confirm these findings, however,
and to establish whether the same risks apply to pa-
tients undergoing pharmacological cardioversion.
Crijns et al. recently reported on a prospective inter-
national, multicentre, observational cardioversion study:
the International Registry on Cardioversion of Atrial
Fibrillation (RHYTHM-AF) [3]. A total of 3940 con-
secutive patients with recent-onset AF considered for
cardioversion were enrolled between May 2010 and
June 2011. Overall, cardioversion was performed at a me-
dian (interquartile range) of 4.0 (1.4–25.5) hours after ad-
mission (after 6 [2.4–40.0] hours for ECV [n = 1946] and
after 1.7 [0.6–8.7] hours for pharmacological cardioversion
[n = 1026]); no cardioversion was performed in an
additional 968 patients. One patient in each group
died and one individual in each group experienced heart
failure within 5 days of admission. In the 5–70-day follow-
up period, there were 6 (0.31 %), 7 (0.68 %) and 9 (0.93 %)
deaths, as well as 8 (0.41 %), 4 (0.39 %) and 4 (0.41 %)
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incidents of heart failure, in the ECV, pharmacological
cardioversion and no cardioversion groups, respectively.
Taken together, these studies have revealed that there
is a background level of serious outcomes, including
death, occurring in patients with AF who are candidates
for cardioversion, whether cardioversion is attempted by
electrical or pharmacological means, and even when car-
dioversion is not attempted at all. While confirmation in
prospective randomized trials is necessary, the study by
Nuotio et al. [23] is also suggestive of a potential benefit
of rapid cardioversion (within 12 h) of onset of AF in
order to reduce the risk of thromboembolism in patients
with AF of less than 48 h’ duration. Vernakalant pro-
vides a median time to conversion of 11 min and may
be valuable for the cardioversion of haemodynamically
stable patients with recent-onset AF.
Conclusions
The data from this phase 3b study confirm that vernaka-
lant rapidly and effectively converts recent-onset AF to
SR in patients without CHF, and provides symptom re-
lief. Vernakalant was generally well tolerated, although
there was a higher incidence of AEs in the vernakalant
group than in the placebo group. The safety outcomes in
this study were consistent with those seen with other
therapies in large registries of patients with AF, and af-
firm the need for careful management and selection of
haemodynamically stable candidates for cardioversion.
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